Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.53 AUD | 0.00% | +11.58% | -0.93% |
Apr. 17 | Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice | CI |
Apr. 16 | Recce Pharmaceuticals Advances Production of Anti-Infective Medication | MT |
Sales 2024 * | 5.24M 3.38M | Sales 2025 * | 5.7M 3.68M | Capitalization | 108M 69.67M |
---|---|---|---|---|---|
Net income 2024 * | -15M -9.68M | Net income 2025 * | -33M -21.29M | EV / Sales 2024 * | 21.5 x |
Net Debt 2024 * | 4.43M 2.86M | Net Debt 2025 * | 9.31M 6.01M | EV / Sales 2025 * | 20.6 x |
P/E ratio 2024 * |
-6.63
x | P/E ratio 2025 * |
-3.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.47% |
1 week | +11.58% | ||
Current month | +20.45% | ||
1 month | +23.26% | ||
3 months | -0.93% | ||
6 months | +13.98% | ||
Current year | -0.93% |
Managers | Title | Age | Since |
---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 12-04-30 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Thomas Jarrett
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
John Prendergast
CHM | Chairman | 70 | 18-04-23 |
Alan Dunton
BRD | Director/Board Member | 70 | 20-07-13 |
Director/Board Member | - | 17-11-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 0.53 | 0.00% | 22 386 |
24-04-17 | 0.53 | -3.64% | 113,836 |
24-04-16 | 0.55 | +11.11% | 175,911 |
24-04-15 | 0.495 | -2.94% | 140,938 |
24-04-12 | 0.51 | +7.37% | 239,629 |
Delayed Quote Australian S.E., April 17, 2024 at 11:02 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.93% | 71.8M | |
+28.79% | 673B | |
+24.81% | 551B | |
-7.64% | 348B | |
+15.00% | 317B | |
+5.99% | 288B | |
+2.47% | 210B | |
-0.02% | 204B | |
-9.98% | 195B | |
-11.71% | 145B |
- Stock Market
- Equities
- RCE Stock